Innovative science flourishes in academic research institutions. However, drug discovery requires highly specialized expertise, significant technical resources, and substantial funding. We work with institutions and their faculty to identify novel concepts that might not otherwise be resourced. Together, we will develop IP, de-risk programs early and identify a path forward to a preclinical development candidate.
A dedicated team with extensive scientific, drug discovery, and operational expertise.
Industrialized drug discovery capabilities to drive forward new medicines.
Deep investments in life sciences advancing projects to preclinical drug candidates and beyond.
Moving your science from project feasibility to a preclinical development candidate requires deep operational expertise and a proven track record in R&D. At Autobahn Labs, we bring industry experts and a world class drug discovery team comprised of more than 3,000 Evotec scientists to move your ideas forward.
From medicinal chemistry and genomics to proteomics, CRISPR/shRNA and beyond, our team of drug hunters has a broad range of expertise and a deep understanding of the complexities surrounding concept validation, data replication and research design. We have an eye for clinical and commercial viability, and most importantly, potential patient benefit. We are building meaningful collaborations focused on a common goal.
Single point of contact
3,000+ scientists
Industry experts and advisors
Ongoing research collaboration
Expertise from target ID through IND
For our academic and scientific partners, Autobahn Labs provides industrialized drug discovery technology and tools to accelerate new therapies for promising new targets. Autobahn Labs leverages the capabilities of Evotec, a leader in the drug discovery field with more than 20 years of integrated drug discovery expertise.
Evotec provides state-of-the-art technologies and a platform designed to rapidly progress innovative product approaches. We thoroughly review each potential project to develop a coherent drug discovery plan, no matter how advanced the science. Our excellence in execution combined with a proven drug discovery framework allows us to systematically develop best-in-class and first-in-class differentiated therapeutics.
For academic institutions, funding beyond basic research is one of the most significant roadblocks to advancing scientific ideas. When you partner with Autobahn Labs, we provide the financial capital required to advance compelling science to preclinical drug candidate and secure critical intellectual property.
Our investment strength is fueled by Samsara BioCapital, a prominent life sciences venture capital firm, and KCK Ltd., a family investment fund. Seeking innovative medicines that are therapeutic area- and modality-agnostic, our investors are experienced in drug discovery and development and maintain a long-term investment vision consistent with the drug development lifecycle.
Up to $5 million invested per project
Investing in early stage to preclinical development candidate
Patient capital with a long-term investment strategy
